Eli Lilly (LLY) Offering Possible 26.26% Return Over the Next 9 Calendar Days

Eli Lilly's most recent trend suggests a bullish bias. One trading opportunity on Eli Lilly is a Bull Put Spread using a strike $114.00 short put and a strike $109.00 long put offers a potential 26.26% return on risk over the next 9 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $114.00 by expiration. The full premium credit of $1.04 would be kept by the premium seller. The risk of $3.96 would be incurred if the stock dropped below the $109.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Eli Lilly is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Eli Lilly is bullish.

The RSI indicator is at 55.9 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Eli Lilly

Deal-making in the global health-care sector is set to rebound in 2019, law firm says
Tue, 08 Jan 2019 05:36:00 +0000
Deal-making activity in the fast growing health-care sector is expected to rebound in 2019, law firm Baker McKenzie says. The number of mergers and acquisitions will increase by 7 percent in 2019 to $331 billion, marking a recovery from last year's drop of 5 percent, the firm said in a joint report with Oxford Economics. The report comes as Bristol-Myers Squibb and Eli Lilly announced acquisitions this month focused on cancer drugs.

[$$] Eli Lilly to Buy Loxo Oncology in $8 Billion Deal
Tue, 08 Jan 2019 03:48:43 +0000
Eli Lilly & Co. said it is buying Loxo Oncology Inc. for $8 billion in cash, a deal that expands the biopharmaceutical company’s oncology-treatment portfolio and adds to a string of recent deals in the cancer-treatment space. Lilly, based in Indianapolis, will pay $235 a share, a 68% premium to Loxo’s closing price on Friday of $139.87. Shares of Eli Lilly rose 0.4%.

Lilly makes $8 billion bet on drugs for rare cancers with Loxo Oncology buy
Tue, 08 Jan 2019 03:14:48 +0000
The price represents a 68 percent premium to Loxo's Friday share price close, which some Wall Street analysts said was high for a company with only one drug on the market that it shares with a partner. Loxo shares surged 66 percent to $232.65, close to the offer price of $235 per share, and prompted stock price rises for a other small developers of targeted cancer therapies, including Array BioPharma, Blueprint Medicines Corp and Clovis Oncology Inc. Lilly shares rose 0.5 percent to $115.28. The cash deal comes on the heels of Bristol-Myers Squibb Co's agreement last week to buy Celgene Corp for $74 billion in the largest pharmaceutical deal ever, spurring investors' hopes of a new wave of large healthcare acquisitions.

Gilead, Pfizer Execs Suggest Even More Pharma M&A Is on Way
Tue, 08 Jan 2019 01:44:04 +0000
Eli Lilly & Co. said Monday it will acquire Loxo Oncology Inc. for about $8 billion in cash. The announcement came just days after Bristol-Myers Squibb Co. and Celgene Corp. announced a $74 billion cash-and-stock deal, the biggest pharma deal ever. “First and foremost, we’re focused on M&A,” Gilead Sciences Inc. Chief Financial Officer Robin Washington said Monday at the J.P. Morgan Healthcare Conference in San Francisco.

PRESS DIGEST- Financial Times – Jan 8
Tue, 08 Jan 2019 01:14:58 +0000
The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines Daimler speeds up self-driving trucking technology https://on.ft.com/2REup9O …

Be Sociable, Share!

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.